Trial Profile

A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of golexanolone in subjects with primary biliary cholangitis, fatigue, and cognitive dysfunction.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golexanolone (Primary)
Indications Cholangitis; Cognition disorders; Fatigue; Primary biliary cirrhosis
Focus Adverse reactions
Sponsors Umecrine Cognition

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
18 Nov 2022 According to a Karolinska Development AB media release, the Umecrine Cognition has secured funding of SEK 41 million for the start of the Phase 2 part of this study.
01 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com